First Time Loading...

Janux Therapeutics Inc
NASDAQ:JANX

Watchlist Manager
Janux Therapeutics Inc Logo
Janux Therapeutics Inc
NASDAQ:JANX
Watchlist
Price: 56.08 USD 18.34% Market Closed
Updated: Apr 30, 2024

Intrinsic Value

JANX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. [ Read More ]

The intrinsic value of one JANX stock under the Base Case scenario is 2.22 USD. Compared to the current market price of 56.08 USD, Janux Therapeutics Inc is Overvalued by 96%.

Key Points:
JANX Intrinsic Value
Base Case
2.22 USD
Overvaluation 96%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Janux Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling JANX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Janux Therapeutics Inc

Provide an overview of the primary business activities
of Janux Therapeutics Inc.

What unique competitive advantages
does Janux Therapeutics Inc hold over its rivals?

What risks and challenges
does Janux Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Janux Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Janux Therapeutics Inc.

Provide P/S
for Janux Therapeutics Inc.

Provide P/E
for Janux Therapeutics Inc.

Provide P/OCF
for Janux Therapeutics Inc.

Provide P/FCFE
for Janux Therapeutics Inc.

Provide P/B
for Janux Therapeutics Inc.

Provide EV/S
for Janux Therapeutics Inc.

Provide EV/GP
for Janux Therapeutics Inc.

Provide EV/EBITDA
for Janux Therapeutics Inc.

Provide EV/EBIT
for Janux Therapeutics Inc.

Provide EV/OCF
for Janux Therapeutics Inc.

Provide EV/FCFF
for Janux Therapeutics Inc.

Provide EV/IC
for Janux Therapeutics Inc.

Show me price targets
for Janux Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Janux Therapeutics Inc?

How accurate were the past Revenue estimates
for Janux Therapeutics Inc?

What are the Net Income projections
for Janux Therapeutics Inc?

How accurate were the past Net Income estimates
for Janux Therapeutics Inc?

What are the EPS projections
for Janux Therapeutics Inc?

How accurate were the past EPS estimates
for Janux Therapeutics Inc?

What are the EBIT projections
for Janux Therapeutics Inc?

How accurate were the past EBIT estimates
for Janux Therapeutics Inc?

Compare the revenue forecasts
for Janux Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Janux Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Janux Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Janux Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Janux Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Janux Therapeutics Inc with its peers.

Analyze the financial leverage
of Janux Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Janux Therapeutics Inc.

Provide ROE
for Janux Therapeutics Inc.

Provide ROA
for Janux Therapeutics Inc.

Provide ROIC
for Janux Therapeutics Inc.

Provide ROCE
for Janux Therapeutics Inc.

Provide Gross Margin
for Janux Therapeutics Inc.

Provide Operating Margin
for Janux Therapeutics Inc.

Provide Net Margin
for Janux Therapeutics Inc.

Provide FCF Margin
for Janux Therapeutics Inc.

Show all solvency ratios
for Janux Therapeutics Inc.

Provide D/E Ratio
for Janux Therapeutics Inc.

Provide D/A Ratio
for Janux Therapeutics Inc.

Provide Interest Coverage Ratio
for Janux Therapeutics Inc.

Provide Altman Z-Score Ratio
for Janux Therapeutics Inc.

Provide Quick Ratio
for Janux Therapeutics Inc.

Provide Current Ratio
for Janux Therapeutics Inc.

Provide Cash Ratio
for Janux Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Janux Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Janux Therapeutics Inc?

What is the current Free Cash Flow
of Janux Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Janux Therapeutics Inc.

Financials

Balance Sheet Decomposition
Janux Therapeutics Inc

Current Assets 349.2m
Cash & Short-Term Investments 344m
Other Current Assets 5.2m
Non-Current Assets 31.2m
PP&E 27.8m
Other Non-Current Assets 3.3m
Current Liabilities 13m
Accounts Payable 2.4m
Accrued Liabilities 8.9m
Other Current Liabilities 1.7m
Non-Current Liabilities 23m
Other Non-Current Liabilities 23m
Efficiency

Earnings Waterfall
Janux Therapeutics Inc

Revenue
8.1m USD
Operating Expenses
-81.1m USD
Operating Income
-73m USD
Other Expenses
14.7m USD
Net Income
-58.3m USD

Free Cash Flow Analysis
Janux Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

JANX Profitability Score
Profitability Due Diligence

Janux Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
24/100
Profitability
Score

Janux Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

JANX Solvency Score
Solvency Due Diligence

Janux Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Janux Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

JANX Price Targets Summary
Janux Therapeutics Inc

Wall Street analysts forecast JANX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JANX is 57.46 USD with a low forecast of 25.25 USD and a high forecast of 105 USD.

Lowest
Price Target
25.25 USD
55% Downside
Average
Price Target
57.46 USD
2% Upside
Highest
Price Target
105 USD
87% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

JANX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

JANX Price
Janux Therapeutics Inc

1M 1M
+49%
6M 6M
+815%
1Y 1Y
+265%
3Y 3Y
+230%
5Y 5Y
+230%
10Y 10Y
+230%
Annual Price Range
56.08
52w Low
5.85
52w High
56.08
Price Metrics
Average Annual Return -5.84%
Standard Deviation of Annual Returns 35.21%
Max Drawdown -83%
Shares Statistics
Market Capitalization 2.9B USD
Shares Outstanding 51 660 100
Percentage of Shares Shorted 14.23%

JANX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Janux Therapeutics Inc Logo
Janux Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.9B USD

Dividend Yield

0%

Description

Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 33 full-time employees. The company went IPO on 2021-06-11. The firm is engaged in developing therapeutics based on its Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. Its focus is on developing a class of T cell engagers (TCEs). The company is developing a broad pipeline with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Its pipeline includes PSMA-TRACTr, EGFR-TRACTr and TROP2-TRACTr. The firm's PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. Its EGFR-TRACTr is designed to target EGFR. TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target. The firm is also applying its technology to develop a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and CD28.

Contact

CALIFORNIA
San Diego
11099 Torrey Pines Park Road
+18587504700.0
https://www.januxrx.com/

IPO

2021-06-11

Employees

33

Officers

President, CEO & Director
Dr. David Alan Campbell Ph.D.
Chief Strategy Officer
Mr. Byron Robinson J.D., Ph.D.
Acting Chief Financial Officer
Mr. Tighe M. Reardon C.F.A., CPA
Chief Technical Officer
Mr. Charles M. Winter
Chief Scientific Officer
Dr. Tommy Diraimondo Ph.D.
General Counsel
Mr. James Pennington
Show More
Head of Human Resources
Ms. Brenda Van Vreeswyk
Chief Business Officer
Mr. Andy Hollman Meyer
Show Less

See Also

Discover More
What is the Intrinsic Value of one JANX stock?

The intrinsic value of one JANX stock under the Base Case scenario is 2.22 USD.

Is JANX stock undervalued or overvalued?

Compared to the current market price of 56.08 USD, Janux Therapeutics Inc is Overvalued by 96%.